Recombinant factor VIII Fc for the treatment of haemophilia A
نویسندگان
چکیده
منابع مشابه
Haemophilia A (Factor VIII Deficiency)
This is a bleeding disorder caused by deficiency of clotting factor VIII. The vast majority of cases are inherited but acquired forms do exist, largely in older patients, due to autoantibodies directed against factor VIII or haematological malignancy. [2] Severity of disease depends upon levels of remaining factor activity, with normal range expressed as 50-200% (refer to local laboratory for r...
متن کاملHaemophilia A (Factor VIII Deficiency)
This is a bleeding disorder caused by deficiency of clotting factor VIII. The vast majority of cases are inherited but acquired forms do exist, largely in older patients, due to autoantibodies directed against factor VIII or haematological malignancy. [2] Severity of disease depends upon levels of remaining factor activity, with normal range expressed as 50-200% (refer to local laboratory for r...
متن کاملPhysical activity in individuals with haemophilia and experience with recombinant factor VIII Fc fusion protein and recombinant factor IX Fc fusion protein for the treatment of active patients: a literature review and case reports
The World Federation of Hemophilia and the National Hemophilia Foundation encourage people with haemophilia (PWH) to participate in routine physical activity. The benefits of physical activity for PWH include improvements in joint, bone, and muscle health. Accordingly, a number of studies suggest that levels of physical activity among PWH are similar to those of their healthy peers, especially ...
متن کاملRecombinant factor VIII Fc fusion protein for the prevention and treatment of bleeding in children with severe hemophilia A.
BACKGROUND Prophylactic factor replacement, which prevents hemarthroses and thereby reduces the musculoskeletal disease burden in children with hemophilia A, requires frequent intravenous infusions (three to four times weekly). OBJECTIVE Kids A-LONG was a phase 3 open-label study evaluating the safety, efficacy and pharmacokinetics of a longer-acting factor, recombinant factor VIII Fc fusion ...
متن کاملProlonged activity of a recombinant factor VIII-Fc fusion protein in hemophilia A mice and dogs.
Despite proven benefits, prophylactic treatment for hemophilia A is hampered by the short half-life of factor VIII. A recombinant factor VIII-Fc fusion protein (rFVIIIFc) was constructed to determine the potential for reduced frequency of dosing. rFVIIIFc has an ∼ 2-fold longer half-life than rFVIII in hemophilia A (HemA) mice and dogs. The extension of rFVIIIFc half-life requires interaction o...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: European Journal of Haematology
سال: 2021
ISSN: 0902-4441,1600-0609
DOI: 10.1111/ejh.13610